ImmunoGen, Inc.

IMGNUnited States

33 filed reports · 358 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$109M

FY2022 · to Dec 31, 2022

up +55.7% vs $69.9M

10-K

Net income

-$223M

FY2022 · to Dec 31, 2022

a year earlier: -$139M

10-K

Operating income

-$221M

FY2022 · to Dec 31, 2022

a year earlier: -$125M

10-K

Latest quarter

Revenue

$113M

Q3 FY2023 · to Sep 30, 2023

up +638% vs $15.4M

10-Q

Net income

$30.7M

Q3 FY2023 · to Sep 30, 2023

a year earlier: -$77.8M

10-Q

Operating income

$26M

Q3 FY2023 · to Sep 30, 2023

a year earlier: -$77.4M

10-Q

Filed reports

33 reports · Jun 2015 to Sep 2023

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR253,039Sep 2015 to Sep 2023
Annual · 10-KSEC EDGAR82,958Jun 2015 to Dec 2022

Documents

PeriodTypePeriod endPublishedFactsSource
FY2023 Q310-Q2023-09-302023-11-02294Open
FY2023 Q210-Q2023-06-302023-07-31144Open
FY2023 Q110-Q2023-03-312023-04-28145Open
FY202210-K2022-12-312023-03-01582Open
FY2022 Q310-Q2022-09-302022-11-04118Open
FY2022 Q210-Q2022-06-302022-08-0187Open
FY2022 Q110-Q2022-03-312022-05-06112Open
FY202110-K2021-12-312022-02-28303Open
FY2021 Q310-Q2021-09-302021-10-29138Open
FY2021 Q210-Q2021-06-302021-07-30116Open
FY2021 Q110-Q2021-03-312021-05-10121Open
FY202010-K2020-12-312021-03-01303Open

Financial data

358 concepts · 5,997 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial351 concepts · 5,818 facts · Jun 2013 to Sep 2023

  • Cash and cash equivalents at carrying value52 · Jun 2013 to Sep 2023
  • Operating expenses (US GAAP)52 · Jun 2013 to Sep 2023
  • Operating income loss52 · Jun 2013 to Sep 2023
  • Research and development expense52 · Jun 2013 to Sep 2023
  • Revenue52 · Jun 2013 to Sep 2023
  • Stockholders equity (US GAAP)49 · Jun 2013 to Sep 2023
  • Investment income net48 · Jun 2013 to Sep 2023
  • Other nonoperating income expense48 · Jun 2013 to Sep 2023
  • Accounts payable current47 · Jun 2014 to Sep 2023
  • Additional paid in capital common stock47 · Jun 2014 to Sep 2023
  • Assets47 · Jun 2014 to Sep 2023
  • Assets current47 · Jun 2014 to Sep 2023
  • Common stock value47 · Jun 2014 to Sep 2023
  • Depreciation depletion and amortization47 · Jun 2013 to Sep 2023
  • Employee related liabilities current47 · Jun 2014 to Sep 2023
  • Increase decrease in accounts payable47 · Jun 2013 to Sep 2023
  • Increase decrease in accounts receivable47 · Jun 2013 to Sep 2023
  • Increase decrease in employee related liabilities47 · Jun 2013 to Sep 2023
  • Increase decrease in other accrued liabilities47 · Jun 2013 to Sep 2023
  • Increase decrease in other operating assets47 · Jun 2013 to Sep 2023
  • Increase decrease in prepaid deferred expense and other assets47 · Jun 2013 to Sep 2023
  • Liabilities47 · Jun 2014 to Sep 2023
  • Liabilities and stockholders equity47 · Jun 2014 to Sep 2023
  • Liabilities current47 · Jun 2014 to Sep 2023

Product7 concepts · 179 facts · Sep 2015 to Sep 2023

  • Revenue165 · Sep 2015 to Sep 2023
  • Contract with customer liability revenue recognized4 · Mar 2018 to Dec 2022
  • Increase decrease in royalties payable4 · Sep 2019 to Sep 2020
  • Revenue from related parties2 · Dec 2021 to Dec 2022
  • Royalty Revenue Percentage If Applicable Threshold Is Met2 · Dec 2015
  • Maximum Amount Entitled to Receive1 · Dec 2022
  • Transaction Costs Amortized to Interest Expense1 · Mar 2020

Segments

179 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or servicesrt:ProductOrServiceAxis8 members · 177 facts

  • License and milestone fees46 · Sep 2015 to Sep 2023
  • Non-cash royalty revenue related to the sale of future royalties41 · Sep 2015 to Sep 2023
  • Research and development support41 · Sep 2015 to Sep 2023
  • Product20 · Dec 2018 to Sep 2022
  • Clinical materials revenue18 · Sep 2015 to Dec 2018
  • Kadcyla6 · Dec 2015 to Sep 2020
  • Royalty revenue3 · Sep 2015 to Jun 2016
  • Future Technological Improvements2 · Mar 2022 to Sep 2023

Product or serviceus-gaap:ProductOrServiceAxis2 members · 2 facts

  • Future Technological Improvements1 · Mar 2018
  • Kadcyla1 · Dec 2015

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of ImmunoGen, Inc. (IMGN) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.

ImmunoGen, Inc. (IMGN): FY2022 revenue $109M · FactIQ